Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mission Pharmacal Citracal superior calcium bioavailability claims unsupported -- NAD.

This article was originally published in The Tan Sheet

Executive Summary

CITRACAL SUPERIOR CALCIUM BIOAVAILABILITY CLAIMS UNSUPPORTED, the National Advertising Division of the Council of Better Business Bureaus concludes in an Aug. 5 NAD Case Report. Mission Pharmacal ads for Citracal were challenged by SmithKline Beecham, the maker of Tums and Os Cal calcium supplements. Based in San Antonio, Mission Pharmacal maintains its claims are "clearly supported by clinical data, including a number of studies published in peer reviewed medical and clinical research journals." The company is appealing the NAD decision to the National Advertising Review Board.
Advertisement

Related Content

Os-Cal, Citracal Parity Claims Modification Recommended By NAD
Os-Cal, Citracal Parity Claims Modification Recommended By NAD
Os-Cal, Citracal Parity Claims Modification Recommended By NAD

Topics

Advertisement
UsernamePublicRestriction

Register

PS088742

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel